Biological age acceleration and pancreatic disease risk in 326,873 UK Biobank adults
In a UK Biobank cohort of 326,873 adults, higher biological age acceleration scores were associated with higher risks of pancreatic diseases, including pancreatic cancer and pancreas-related mortality; lipid biomarkers partially mediated these associations. [1]
Automatic summary · not editorially reviewed
The key findings
The study included 326,873 UK Biobank adults recruited in 2006–2010 and examined biological age acceleration scores against pancreatic disease outcomes. [1]
Compared with G1, the PhenoAgeAccel G4 group had higher risks of all pancreatic diseases, acute and chronic pancreatitis, pancreatic cysts, pancreatic cancer and pancreas-related mortality. [1]
Circulating lipid biomarkers partially mediated the association between PhenoAgeAccel and pancreatic diseases. [1]
The source at a glance
- Study type / format
- Prospective cohort study (abstract)
- Population / context
- 326,873 adults in the UK Biobank recruited in 2006–2010
- Summary based on
- Study abstract
- Original publication
- September 15, 2026
UK Biobank cohort of 326,873 adults
This prospective cohort study used UK Biobank data from 326,873 adults recruited between 2006 and 2010. The researchers measured two biological age acceleration scores, KDMAgeAccel and PhenoAgeAccel, and grouped participants into four categories (G1–G4) by standard deviation; they also modeled the scores continuously. They then examined associations with overall pancreatic diseases, acute pancreatitis, chronic pancreatitis, pancreatic cysts, pancreatic cancer and pancreas-related mortality.
Supporting source [1]
Higher PhenoAgeAccel linked to pancreatic disease risks
In the fully adjusted Cox model, the PhenoAgeAccel G4 group had higher risks than G1 for all pancreatic diseases (hazard ratio 1.706, 95% confidence interval 1.513–1.923), acute pancreatitis (1.637, 1.352–1.981), chronic pancreatitis (3.551, 2.248–5.609), pancreatic cysts (1.547, 1.128–2.122), pancreatic cancer (1.387, 1.123–1.713) and pancreas-related mortality (1.442, 1.139–1.824). These are associations, not evidence that biological age acceleration causes pancreatic disease.
Supporting source [1]
Lipid biomarkers as partial statistical mediators
Circulating lipid biomarkers partially mediated the association between PhenoAgeAccel and pancreatic diseases. Notable contributions were free cholesterol in small LDL (6.66% for chronic pancreatitis), the cholesterol to total lipids ratio in medium LDL (8.54% for acute pancreatitis) and the cholesterol to total lipids ratio in large LDL (8.06% for pancreatic cancer). The authors describe these as potential statistical mediators and suggest possible implications for clinical risk stratification.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports a prospective cohort design and hazard ratios but does not detail follow-up length, adjustment variables, or how biological age acceleration was measured. The findings are associations, and the lipid biomarkers are described as potential statistical mediators, not established causal pathways.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhang H, Huang J, Lin P, Song J, Hu C, Lin B, Le L, Zheng S. · europepmc.org · September 15, 2026